Overview
Switzerland hearing solutions provider's FY 2025/26 revenue rose 5.9% in local currencies
Normalized EBITA grew 17.3% in local currencies, reflecting strong operating leverage
Company proposes record CHF 4.70 per share dividend for FY 2025/26
Outlook
Sonova expects 2026/27 consolidated sales growth of 5-8% at constant exchange rates
Company sees 2026/27 core EBIT growth of 7-10% at constant exchange rates
Sonova expects currency effects to reduce reported sales growth by 1-2 percentage points in 2026/27
Result Drivers
PRODUCT LAUNCHES - Sonova said successful launches of Infinio Ultra and Virto R Infinio hearing aids drove sales and market share gains
RETAIL INITIATIVES - Targeted lead-generation and cost-efficiency measures in Retail business contributed to above-market growth and improved profitability
COCHLEAR IMPLANTS HEADWINDS - Cochlear Implants segment faced lower sales due to challenges in China and increased competition in developed markets
Company press release: ID:nEQ8FtrF0a
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
CHF 3.61 bln
FY Adjusted EBITA
CHF 811.20 mln
FY EBITA
CHF 724.20 mln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 9 "hold" and 5 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Sonova Holding AG is CHF210.00, about 17.3% above its May 15 closing price of CHF179.10
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 20 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)